Using fine needle aspirates from 25 patients who were under standard treatment for melanoma (including IFN-α), they performed gene analysis and saw that markers of an active T cell response, such as IRF1, IRF2 and TLA-1, were present in lesions that responded to treatment. The gene discussed is IRF2; the disease is melanoma.